UK biotech Circassia has finally given up on its allergy drug development business, citing difficulties in overcoming a strong placebo effect in the trials required for approval by regulators. After a ...

The UK biotech company is putting its huge failure in allergy treatment behind it with a new deal with AstraZeneca (AZ). But British venture capital leader David Grainger is highly critical of the ...

With the business potentially at an important milestone, we thought we'd take a closer look at Circassia Group Plc's (LON:CIR) future prospects. Circassia Group Plc, a medical device company, focuses ...

Every investor in Circassia Group Plc (LON:CIR) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a ...

British biotech Circassia has announced the death of its allergy programme following a second key trial failure, choosing to focus all of its efforts on its respiratory business instead. British ...

- Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ...

Shares in UK biotech Circassia have plummeted after its flagship experimental cat allergy drug failed to hit targets in a Phase III trial. Shares in UK biotech Circassia have plummeted after its ...

OXFORD, England, September 11, 2012--Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann ...

A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble By Paul Sandle LONDON (Reuters) - Britain's Circassia has secured the U.S. rights from ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in UK pharma group Circassia jumped almost 10 per cent on Thursday morning after its partner AstraZeneca ...